598 related articles for article (PubMed ID: 28693973)
1. Rationally combining immunotherapies to improve efficacy of immune checkpoint blockade in solid tumors.
Dammeijer F; Lau SP; van Eijck CHJ; van der Burg SH; Aerts JGJV
Cytokine Growth Factor Rev; 2017 Aug; 36():5-15. PubMed ID: 28693973
[TBL] [Abstract][Full Text] [Related]
2. Coinhibitory Pathways in Immunotherapy for Cancer.
Baumeister SH; Freeman GJ; Dranoff G; Sharpe AH
Annu Rev Immunol; 2016 May; 34():539-73. PubMed ID: 26927206
[TBL] [Abstract][Full Text] [Related]
3. Constitutive and acquired mechanisms of resistance to immune checkpoint blockade in human cancer.
Bellone M; Elia AR
Cytokine Growth Factor Rev; 2017 Aug; 36():17-24. PubMed ID: 28606732
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
Hargadon KM; Johnson CE; Williams CJ
Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of Resistance to Checkpoint Blockade Therapy.
Shi H; Lan J; Yang J
Adv Exp Med Biol; 2020; 1248():83-117. PubMed ID: 32185708
[TBL] [Abstract][Full Text] [Related]
6. Towards In Silico Prediction of the Immune-Checkpoint Blockade Response.
Chen K; Ye H; Lu XJ; Sun B; Liu Q
Trends Pharmacol Sci; 2017 Dec; 38(12):1041-1051. PubMed ID: 29089139
[TBL] [Abstract][Full Text] [Related]
7. Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade.
House IG; Savas P; Lai J; Chen AXY; Oliver AJ; Teo ZL; Todd KL; Henderson MA; Giuffrida L; Petley EV; Sek K; Mardiana S; Gide TN; Quek C; Scolyer RA; Long GV; Wilmott JS; Loi S; Darcy PK; Beavis PA
Clin Cancer Res; 2020 Jan; 26(2):487-504. PubMed ID: 31636098
[TBL] [Abstract][Full Text] [Related]
8. New checkpoints in cancer immunotherapy.
Ni L; Dong C
Immunol Rev; 2017 Mar; 276(1):52-65. PubMed ID: 28258699
[TBL] [Abstract][Full Text] [Related]
9. [Cancer immunotherapy by immuno-checkpoint blockade].
Kawakami Y
Rinsho Ketsueki; 2015 Oct; 56(10):2186-94. PubMed ID: 26458459
[TBL] [Abstract][Full Text] [Related]
10. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.
Dougall WC; Kurtulus S; Smyth MJ; Anderson AC
Immunol Rev; 2017 Mar; 276(1):112-120. PubMed ID: 28258695
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint combinations from mouse to man.
Ai M; Curran MA
Cancer Immunol Immunother; 2015 Jul; 64(7):885-92. PubMed ID: 25555570
[TBL] [Abstract][Full Text] [Related]
12. FcγR-Binding Is an Important Functional Attribute for Immune Checkpoint Antibodies in Cancer Immunotherapy.
Chen X; Song X; Li K; Zhang T
Front Immunol; 2019; 10():292. PubMed ID: 30863404
[TBL] [Abstract][Full Text] [Related]
13. Neoantigen heterogeneity: a key driver of immune response and sensitivity to immune checkpoint blockade?
Furness AJ; Quezada SA; Peggs KS
Immunotherapy; 2016 Jun; 8(7):763-6. PubMed ID: 27349975
[No Abstract] [Full Text] [Related]
14. Immune Checkpoint-Mediated Interactions Between Cancer and Immune Cells in Prostate Adenocarcinoma and Melanoma.
Elia AR; Caputo S; Bellone M
Front Immunol; 2018; 9():1786. PubMed ID: 30108594
[TBL] [Abstract][Full Text] [Related]
15. The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment.
Pennock GK; Chow LQ
Oncologist; 2015 Jul; 20(7):812-22. PubMed ID: 26069281
[TBL] [Abstract][Full Text] [Related]
16. Monitoring immune-checkpoint blockade: response evaluation and biomarker development.
Nishino M; Ramaiya NH; Hatabu H; Hodi FS
Nat Rev Clin Oncol; 2017 Nov; 14(11):655-668. PubMed ID: 28653677
[TBL] [Abstract][Full Text] [Related]
17. Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer.
Borcherding N; Kolb R; Gullicksrud J; Vikas P; Zhu Y; Zhang W
J Mol Biol; 2018 Jul; 430(14):2014-2029. PubMed ID: 29800567
[TBL] [Abstract][Full Text] [Related]
18. The future of immune checkpoint cancer therapy after PD-1 and CTLA-4.
Hahn AW; Gill DM; Pal SK; Agarwal N
Immunotherapy; 2017 Jun; 9(8):681-692. PubMed ID: 28653573
[TBL] [Abstract][Full Text] [Related]
19. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
[TBL] [Abstract][Full Text] [Related]
20. The role of neoantigens in response to immune checkpoint blockade.
Riaz N; Morris L; Havel JJ; Makarov V; Desrichard A; Chan TA
Int Immunol; 2016 Aug; 28(8):411-9. PubMed ID: 27048318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
